First and Only Clinically Validated Circulating TTMV DNA Blood Test Detects HPV-Driven Cancer

Now, an innovative and accessible blood test can potentially enhance patient outcomes by allowing doctors to choose the most appropriate treatment options for each patient, aiming to improve results while minimizing side effects and treatment-related morbidity.

Naveris, Inc.’s (Waltham, MA, USA) flagship blood test, NavDx, detects tumor tissue modified viral (TTMV)-HPV DNA, offering a non-invasive and accurate method for monitoring molecular residual disease (MRD) and recurrence by examining tumor-derived viral DNA in blood samples. NavDx employs proprietary technology to measure circulating TTMV HPV DNA fragments, a unique biomarker specific to HPV-driven cancer that cancer cells release into the blood. The highly accurate blood test reliably detects the presence of HPV+ head and neck cancer throughout the care continuum. NavDx is the first and only clinically validated circulating TTMV DNA blood test that assists in detecting HPV-driven cancer.

By precisely evaluating treatment response, identifying post-treatment MRD presence, and conveniently monitoring recurrence, NavDx optimizes clinical management of HPV-driven cancer. The easy-to-understand, actionable NavDx test report supports clinical decision-making, enabling doctors to treat earlier, potentially leading to better outcomes. Naveris has now initiated a prospective clinical trial to further assess NavDx's ability to enhance treatment selection for patients with HPV-driven head and neck cancer.

"This clinical trial represents a significant step forward in personalized medicine for head and neck cancer patients," said Piyush B. Gupta PhD, Founder and CEO of Naveris. "NavDx has the potential to be a game-changer in treatment selection, allowing physicians to tailor treatment plans to individual patients based on their unique biomarker profiles."

Related Links:
Naveris, Inc.